✦ LIBER ✦

Phase II evaluation of bisantrene in refractory multiple myeloma

✍ Scribed by Brian G. M. Durie; John Crowley; Charles A. Coltman; Robert A. Chapman; Stanley P. Balcerzk; John D. Bonnet; David A. Lipschitz; Ronald L. Stephens; Bruce D. Cheson

Publisher: Springer US
Year: 1991
Tongue: English
Weight: 205 KB
Volume: 9
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00183574

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II evaluation of bisantrene hydroc

Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma

✍ David S. Alberts; Nancy Mason-Liddil; Stephanie J. Green; John D. Cowan; William 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 250 KB

Patients with a pathologically proven diagnosis of malignant melanoma were entered into a phase II trial of bisantrene. Eligibility criteria included: measurable, metastatic disease; performance status 0-2 SWOG; and adriamycin total cumulative dose of < 400 mg/m 2. The initial bisantrene dosing sche

Phase II study of carboplatin (CBDCA) in

Phase II study of carboplatin (CBDCA) in refractory multiple myeloma

✍ Bart Barlogie; John Crowley; Sydney E. Salmon; John Bonnet; James K. Weick; Kath 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 233 KB

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

Phase II trial of amsacrine in patients

Phase II trial of amsacrine in patients with multiple myeloma

✍ Greipp, Philip R. ;Coleman, Morton ;Anderson, Keaven ;McIntyre, O. Ross 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Seventy-four previously treated patients with multiple myeloma were treated with Amsacrine (m-AMSA) 120 mg/m2 every 3 weeks. A good response was observed in two patients (3%), and improvement was seen in three patients (4%). Severe toxicity was observed in 33% of patients who received three or more

A phase II study of bisantrene in malign

A phase II study of bisantrene in malignant lymphomas

✍ Thomas P. Miller; John D. Cowan; Barbara A. Neilan; Stephen E. Jones 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 291 KB

Combination of interferon and dexamethas

Combination of interferon and dexamethasone in refractory multiple myeloma

✍ J. F. San Miguel; M. Moro; J. Bladé; L. Guerras; J. Hernandez; R. Jimenez-Galind 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB

The present pilot study was designed to analyse the efficacy and toxicity of the association of interferon (IFN) and dexamethasone (Dx) in 32 resistant and relapsed myeloma patients. Among the evaluable cases, 15 (68 per cent) responded to treatment (32 per cent achieved an objective respons4R-and 3